AA
ESPR

Antipodean Advisors’s Esperion Therapeutics ESPR Stock Holding History

Antipodean Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-91,000
Closed -$3.21M – 17
2017
Q1 		$3.21M Buy
+91,000
New +$2.08M 1.57% 13

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Antipodean Advisors's ESPR Position: Q2 2017 in Review

Antipodean Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2017, closing a stake of 91,000 shares — an estimated $3.21M sold.

Antipodean Advisors first reported a position in ESPR in Q1 2017 and held it in 1 quarter. The position peaked at $3.21M in Q1 2017. 131 funds tracked by Wall St. Rank hold ESPR as of Q2 2017.

  • Antipodean Advisors reported no remaining Esperion Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Antipodean Advisors sold 91,000 Esperion Therapeutics shares in Q2 2017, an estimated $3.21M.
  • Antipodean Advisors first reported a position in Esperion Therapeutics in Q1 2017 and held it in 1 quarter.
  • Antipodean Advisors's Esperion Therapeutics position peaked at $3.21M in Q1 2017.
  • 131 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2017.

Based on Antipodean Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.